Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients

Annals of Oncology

Volumn 18, Issue 10, 2007, Pages 1660-1665

  Mandalà, Mario ^a   Reni, M ^b   Cascinu, S ^c   Barni, S ^d   Floriani, I ^e   Cereda, S ^b   Berardi, R ^c   Mosconi, S ^a   Torri, V ^e   Labianca, R ^a  

^a OSPEDALI RIUNITI   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d TREVIGLIO HOSPITAL   (Italy)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Pancreatic cancer; Prognosis; Venous thromboembolism

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; VENOUS THROMBOEMBOLISM;

EID: 34848871880     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm284     Document Type: Article

References (25)

1. Rickels FR, Levine M, Edwards RL. Hemostatic in cancer patients. Cancer Metastasis Rev 1992; 1: 237-248.
2. Otten HM, Mathijssen J, ten Cate H et al. Symptomatic venous thromboembolism in cancer patents treated with chemotherapy, an underestimated phenomenon Arch Intern Med 2004; 164: 190-194.
3. Kosuri K, Muscarella P, BeKaii-Saab TS, Updates and controversies in the treatment of pancreatic cancer. Clin Adv Hematol Oncol 2006; 4: 47-54.
4. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 10-23.
5. Falanga A. The effect of anticoagulant drugs on cancer. J Thromb Haemost 2004; 2: 1-3.
6. Sorensen HT, Mellemkjaer L, Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
7. Chew HK, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
8. Cascinu S, Lablanca R, Catalano V et al. Weekly gemcitabine and cisplatin chemotherapy: A well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 2003; 14: 205-208.
9. Reni M, Cordio S, Milandri C et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6: 369-376.
10. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004; 5: 655-663.
11. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am 1996; 10: 499-530.
12. Falanga A, Rickels FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25: 173-182.
13. Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematol 2001; 106: 25-32.
14. Nitori N, Yoshinori I, Nakanishi Y et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005; 11: 2531-2539.
15. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Haemost 2006; 32: 24-32.
16. Jiang X, Guo YL, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 2006; 96: 196-201.
17. Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: A cohort study of 202 patents. Eur J Cancer 2006; 42: 410-414.
18. Palareti G, Legnani G, Lee A et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patents with or without malignancy. Thromb Haemost 2000; 84: 805-810.
19. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalised ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
20. Lee A, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
21. Khorana AA, Francis CW, Gulakova E et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-490.
22. Alcalay A, Wun T, Khatri V et al. Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival. J Clin Oncol 2006; 24: 1112-1118.
23. Chew HK, Wun T, Harvey DJ et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007; 25: 70-76.
24. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004; 15: 1944-1948.
25. Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 1: 2130-2135.